This page is intended for Irish Healthcare Professionals only
NVP is a condition that can affect up to 80% of expectant mothers.4 It can have a significant impact on the expectant mother’s family life, on the ability to perform usual daily activities, on social functioning, and on stress levels.5,6
The most severe form of NVP is commonly known as Hyperemesis Gravidarum (HG) which can affect up to 3.6% of pregnant women.9
Evidence suggests that recognising and managing NVP early may prevent a more severe form from developing. This can also reduce the impact on women’s health and quality of life during pregnancy, as well as the financial impact on the health care system. 6
Cariban is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management. (Limitations of use: The combination doxylamine/pyridoxine has not been studied in case of hyperemesis gravidarum)1
NVP is diagnosed when onset is prior to 16 weeks of gestation and other causes of nausea and vomiting have been excluded.
The most severe form of NVP can be diagnosed when symptoms start in early pregnancy, nausea and/or vomiting are severe enough to cause an inability to eat and drink normally and strongly limits daily activities of living. Signs of dehydration are contributory to diagnosis.9
An objective and validated scoring index of nausea and vomiting such as the Pregnancy-Unique Quantification of Emesis (PUQE) tool can be used to classify the severity of NVP.9
For those who fail to respond to conservative management, Cariban is the first-line pharmacological treatment recommended for NVP according to Irish clinical guidelines.2
Ensure you are viewing relevant content
Please select from the following options:
If you have any questions regarding Cariban please contact us directly.